Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.44 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | VDR | P11473 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.37 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14770709 | 0.87 | MEN1 (0.48) | SCN10ACACNA1DPDE2AMEN1KMT2A | |
| SCHEMBL14770549 | 0.86 | ALDH1A1 (0.42) | MEN1KMT2ARAB9APTGESALOX5 | |
| SCHEMBL14770638 | 0.85 | SCN10A (0.52) | SCN10APDE2APTGESALOX5LTC4S | |
| SCHEMBL14770492 | 0.84 | AMY1A (0.41) | SCN10AMEN1KMT2ARAB9APTGES | |
| SCHEMBL14770646 | 0.81 | SCN10A (0.40) | SCN10APDE2AMEN1KMT2ARAB9A | |
| SCHEMBL14770550 | 0.81 | FLT3 (0.40) | MEN1KMT2APTGESALOX5LTC4S | |
| SCHEMBL14770613 | 0.81 | FLT3 (0.40) | MEN1KMT2ARAB9APTGESALOX5 | |
| SCHEMBL14770630 | 0.80 | AMY1A (0.42) | SCN10AMEN1KMT2APTGESALOX5 | |
| SCHEMBL14770529 | 0.79 | FFAR1 (0.38) | SCN10APDE2A | |
| SCHEMBL14770535 | 0.79 | MEN1 (0.53) | MEN1KMT2ARAB9AL3MBTL1PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096531-B2 | Fused imidazole derivative | TOA EIYO LTD. (JP) | 2015-08-04 | — | — | US | disclosed |
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA EIYO LTD. (JP) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | CACNA1E, CACNA1G, CACNA1A | SCN10A 85/4885CACNA1D 10/4885PDE2A 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.